The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
For World AIDS Day, read about stigma, criminalization and more >>
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Press Release

Cause for Caution on the Results of the ALVAC/AIDSVAX HIV Vaccine Efficacy Trial: More Marginal Than "Modest"

September 25, 2009

New York, N.Y. -- Yesterday it was reported that an HIV vaccine regimen led to a marginal but statistically significant degree of protection against acquisition of HIV infection. The only information provided by the trial sponsors in their press releases is that 74 out of 8,198 volunteers who received placebo immunizations became infected with HIV compared to 51 out of 8,197 volunteers who received a combination of two vaccines, ALVAC vCP1521 and AIDSVAX B/E. Seven of the original 16,402 volunteers were excluded from the efficacy analyses after it was found that they were HIV-infected at the time of receiving their first vaccination. The result equates to a protective efficacy of a little over 31%, but with a very wide "95% confidence interval" spanning from 1.1% to 52.1% (a confidence interval is a statistical method for conveying the degree of uncertainty associated with a result; if the lower bound of the confidence interval is less than 1, the result is not statistically significant). The vaccines had no effect on post-infection viral load levels among the recipients who became infected.

These results are very welcome given the many unwelcome surprises that have assailed the HIV vaccine field over the past few years. However, based on the limited amount of information that has been released, it appears that the statistical significance hangs on very few cases of HIV infection. TAG urges caution in interpreting the findings until more detailed information is available. In light of the potential importance of the results to efforts to prevent HIV infection, and the level of public interest, TAG is disappointed that the trial sponsors did not include more data with their news releases.

TAG's Position on the Trial

When the trial was launched, TAG stated our concern that the lack of data on the efficacy of ALVAC alone would preclude an understanding of whether the inclusion of AIDSVAX added to, or subtracted from, any potential benefit (Science 305;5681:180). Now that there is an indication of possible efficacy, this issue looms large. Many people worked diligently and in good faith on this trial and it is disheartening that such a huge undertaking is still unable to provide definitive answers as to the efficacy of the candidates studied. Instead, if the results hold up to scrutiny, more trials will be required to try and understand what happened.

TAG will provide additional information and commentary on the trial results when the details become available.

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Treatment Action Group.
See Also
HIV/AIDS Vaccine Is Found to Be Partly Effective at Preventing HIV Infection, but Advocates Express Skepticism
Investigational Vaccine Shows Modest Potential for Protecting Against HIV Infection
Basic Information on the RV144 Phase III HIV Vaccine Trial
HIV Vaccine Study First to Show Some Effectiveness in Preventing HIV (Press Release From U.S. Military HIV Research Program)
AIDS Vaccine Results: Thai Trial